Form 4 for STLN Starling Oncology, Inc.
Accepted 2025-05-22 00:00:00 ET · period of report 2025-05-21 · accession 0001628280-25-027201 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-22 | 2025-05-21 | STLN | Castle Jeremy | COO | D - Sale to Iss | $2.68 | -5,636 | 247.0K | -2% | -$15.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2025-05-21 | D | D | 5,636 | $2.68 | 247,031 | D | — | — | (F1) The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement. (F2) Price is the selling price of all sales by the Reporting Person on May 21, 2025. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at the certain price. |